Patients are dying because of a cytokine storm and inappropriate autoimmune response with raised IL-6 and CRP levels. The x rays are ground glass and similar to patients with immune checkpoint induced pneumonitis.
And I found a potential answer in THIS FORUM!
EXERPT FROM PREPRESS ARTICLE:
https://www.sitcancer.org/research/covid-19-resources/il-6-editorialIn any case here is a quote from the article as there is already an FDA approved drug Tocilizumab to treat this !!!
Tocilizumab also is already FDA-approved to manage cytokine release syndrome (CRS) in patients receiving CAR T cell therapy [4, 5]. In addition, tocilizumab has been shown to reduce toxicity in patients treated with ICI who were steroid refractory [6], and has been added to the ICI agents ipilimumab and nivolumab in an ongoing US phase II study (NCT03999749) to ameliorate immune-related toxicity. In Castleman's disease, a lymphoproliferative disorder caused by Kaposi's Sarcoma Herpesvirus, a pathogen that produces viral IL-6, tocilizumab has been shown to reduce viral loads [7]. Tocilizumab is also being explored as a potential supportive care measure for the management of CRS in cancer patients treated with a number of CD3-based bispecific molecules. Now, data from the frontlines of the pandemic indicates that the agent may offer lifesaving benefit for COVID-19 patients with respiratory distress.
Emerging evidence suggests that high levels of CRP and IL-6 are observed in patients infected with COVID-19 [1, 8]. Anecdotal experience on the use of tocilizumab at doses comparable to those used for the management of CRS from investigators in Italy [9] and from China [10] has reported rapid improvement in both intubated and non-intubated patients. In these reports, expeditious administration of anti-IL-6R therapy for patients in acute respiratory distress has been critical. A recent study protocol to evaluate the efficacy of tocilizumab in COVID-19 induced pneumonitis accrued over 300 patients worldwide in less than 24 hours. Additionally, Genentech will also provide 10,000 vials of tocilizumab to the U.S. Strategic National Stockpile [11]. Tocilizumab was also approved in China in March 2020, for the treatment of patients with COVID-19 with serious lung damage and elevated IL-6